Kintara Therapeutics Inc (KTRA)

Относно

Kintara Therapeutics Inc, formerly DelMar Pharmaceuticals, Inc., is a clinical-stage drug development company focused on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). VAL-083 is being evaluated in a Phase II clinical trial for the treatment of GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. AL-083 is a small-molecule, a deoxyribonucleic acid (DNA) targeting chemotherapeutic. VAL-083 has accessed over 40 Phase I and Phase II clinical trials sponsored by the National Cancer Institute (NCI).